Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.74 |
| ▸ | NR1H4 | Q96RI1 | 9/20 | 0.74 |
| ▸ | NAMPT | P43490 | 1/20 | 0.61 |
| ▸ | PTPRZ1 | P23471 | 2/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | LSS | P48449 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2288175 | 0.87 | EPHX2 (0.71) | EPHX2NR1H4NAMPTPTPRZ1TRPV1 | |
| SCHEMBL2291083 | 0.85 | EPHX2 (0.68) | EPHX2NR1H4NAMPTPTPRZ1TRPV1 | |
| SCHEMBL2288184 | 0.85 | NR1H4 (0.61) | EPHX2NR1H4NAMPTPTPRZ1TRPV1 | |
| SCHEMBL2288249 | 0.84 | EPHX2 (0.74) | EPHX2NR1H4NAMPTPTPRZ1TRPV1 | |
| SCHEMBL6001754 | 0.83 | EPHX2 (0.73) | EPHX2NR1H4NAMPTPTPRZ1LMNA | |
| SCHEMBL2283424 | 0.83 | EPHX2 (0.73) | EPHX2NR1H4NAMPTPTPRZ1LMNA | |
| SCHEMBL2290753 | 0.82 | SMN1; SMN2 (0.52) | EPHX2NR1H4LMNAMAPTHDAC6 | |
| SCHEMBL27913697 | 0.81 | EPHX2 (0.70) | EPHX2NR1H4NAMPTPTPRZ1LMNA | |
| SCHEMBL2282890 | 0.81 | EPHX2 (0.70) | EPHX2NR1H4NAMPTPTPRZ1TRPV1 | |
| SCHEMBL22193541 | 0.79 | EPHX2 (0.68) | EPHX2NR1H4MAPTHDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2119476-B1 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBVIE INC (US) | 2014-03-19 | — | — | EP | claimed |
| US-7994223-B2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LABORATORIES (US) | 2011-08-09 | — | — | US | claimed |
| US-20100286109-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-11 | — | — | US | claimed |
| US-7786171-B2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LABORATORIES (US) | 2010-08-31 | — | — | US | claimed |
| EP-2119476-A2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LABORATORIES (US) | 2009-11-18 | — | — | EP | claimed |
| US-20090253670-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | claimed |
| EP-2119476-B1 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBVIE INC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-7994223-B2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LABORATORIES (US) | 2011-08-09 | — | — | US | disclosed |
| US-20100286109-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-11 | — | — | US | disclosed |
| US-7786171-B2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LABORATORIES (US) | 2010-08-31 | — | — | US | disclosed |
| EP-2119476-A2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LABORATORIES (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20090253670-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286109-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | CHRNA4, CHRNA2, CHRNA3 | EPHX2 3609/4885NR1H4 1474/4885NAMPT 200/4885 |
| US-20090253670-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | CHRNA4, CHRNA2, CHRNA3 | EPHX2 3609/4885NR1H4 1474/4885NAMPT 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.